Atara Biotherapeutics, Inc. (ATRA)

Oncology Corporate Profile

Stock Performance

21.5000
1.3000

HQ Location

701 Gateway Blvd, Suite 200
South San Francisco, CA 94080

Company Description

Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with debilitating diseases. Atara's lead programs target myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. In September 2014, Atara Biotherapeutics entered into an exclusive option agreement with MSK, under which it has the right to license (pursuant to a negotiated form of license agreement) the exclusive, worldwide rights to three clinical stage T-cell programs, including EBV-CTL, as well as other T-cell programs that are discovered or developed by MSK pursuant to sponsored research funded by the company.

Website: http://www.atarabio.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
WT1-CTLWT1 inhibitorAcute Myelogenous Leukemia (AML)I
ATA-842humanized antibodyCancer cachexiaI
STM-434Activin A inhibitorOvarian cancerI
WT1-CTLWT1 inhibitorVarious cancer typesI

View additional information on product candidates here »

Source


http://www.atarabio.com

Recent News Headlines

Atara Bio's Collaborating Investigators to Present Interim Results from Phase 1 Trial of the Autologous Version of ATA188 in Patients with Progressive Multiple Sclerosis (MS)

3/17/2017 04:04 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., March 17, 2017-- Atara Biotherapeutics, Inc., a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that ...

Atara Bio Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights

3/9/2017 01:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., March 09, 2017-- Atara Biotherapeutics, Inc., a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been ...

Atara Bio to Present at the 35th Annual J.P. Morgan Healthcare Conference

1/4/2017 01:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., Jan. 04, 2017-- Atara Biotherapeutics, Inc., a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been ...

Atara Bio Concludes EMA Scientific Advice and Plans to Submit Conditional Marketing Authorization Application (MAA) in Europe for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, for the Treatment of E

1/3/2017 01:01 pm

[at noodls] - SOUTH SAN FRANCISCO, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening ...

Atara Bio Concludes EMA Scientific Advice and Plans to Submit Conditional Marketing Authorization Application (MAA) in Europe for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, for the Treatment of E

1/3/2017 01:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., Jan. 03, 2017-- Atara Biotherapeutics, Inc., a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been ...

Atara Bio Reaches Agreement with FDA on Design of Phase 3 Trials for its Lead Anti-Cancer Immunotherapy Program, Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, to Support Potential Approval in Two Se

12/12/2016 01:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., Dec. 12, 2016-- Atara Biotherapeutics, Inc., a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, ...

Atara Bio Announces Results from Ongoing Phase 2 Trial of Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) at the American Society of Hematology (ASH) Annual Meeting 2016

12/3/2016 03:03 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., Dec. 03, 2016-- Atara Biotherapeutics, Inc., a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have ...

Atara Bio Announces Third Quarter 2016 Financial Results and Recent Highlights

11/4/2016 12:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., Nov. 04, 2016-- Atara Biotherapeutics, Inc., a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been ...

Atara Bio Announces Third Quarter 2016 Financial Results and Recent Highlights

11/4/2016 12:00 pm

[at noodls] - SOUTH SAN FRANCISCO, Calif., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening ...

Atara Bio's Collaborating Investigators to Present Results from Phase 2 Trial of Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) at the American Society of Hematology (ASH) Annual Meeting 2016

11/3/2016 01:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., Nov. 03, 2016-- Atara Biotherapeutics, Inc., a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have ...